by David Eyre | Sep 1, 2019 | Briefings, US & International
Eli Lilly is the patent holder of a drug called pemetrexed (Lilly brand “Alimta”) that has been the subject of court proceedings in the UK, which we have reported previously. This case concerns a related issue during US proceedings in which the US Federal...
by Sean Hughes | Jan 1, 2019 | Briefings, US & International
The time-consuming and costly regulatory review of new pharmaceuticals led to the Supplementary Protection Certificate (SPC) system being introduced in 1992. The SPC system is designed to compensate for the shortening in effective patent term that arises from the...
by Juliette Boynton | Nov 1, 2018 | Briefings, US & International
Following the UK Supreme Court decision in Actavis v Eli Lilly in which Lord Neuberger concluded that the term “sodium” also covered “potassium” as an equivalent, a judgement was handed down in Milan also concerning the scope of protection of...
by David Eyre | Aug 1, 2018 | Briefings, EPO, US & International
What Are GMO and Why Are They Regulated? Genetically modified organisms are heavily regulated in Europe and indeed most of the Western hemisphere. In Europe this is governed by Directive 2001/18/EC on the deliberate release of GMOs into the environment (the “GMO...
by Sean Hughes | Jul 1, 2018 | Briefings, US & International
NDAs A non-disclosure agreement (NDA) is a legal contract between two or more parties that outlines confidential material, knowledge or information that the concerned parties wish to share with one another but wish to restrict access to third parties. Clients often...
by David Eyre | Mar 1, 2018 | Briefings, US & International
Extending the patent term for such high value patented products can be particularly significant for rights holders even when the additional term is mere days. A supplementary protection certificate is intended to partially compensate a patent holder for the patent...
Recent Comments